The Safety and Effectiveness of Different Doses of Vitamin C in HIV-Infected Patients

This study has been terminated.

Sponsored by:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00001070

Purpose

This is a study to evaluate the tolerance and antiviral effect of oral vitamin C in HIV-infected.

Condition	Intervention
HIV Infections	Drug: Oral Vitamin C

MedlinePlus related topics: AIDS

Drug Information available for: Ascorbic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Dose Comparison, Efficacy Study
Official Title:	A Dose Escalation Study to Evaluate Tolerance and Antiviral Effect of Oral Vitamin C in Two Groups of HIV-Infected Adults

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	DATRI 017
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00001070
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Virus Diseases
Sexually Transmitted Diseases, Viral
HIV Infections
Sexually Transmitted Diseases

Acquired Immunodeficiency Syndrome
Retroviridae Infections
Ascorbic Acid
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

RNA Virus Infections
Slow Virus Diseases
Antioxidants
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs

Infection
Protective Agents
Pharmacologic Actions
Vitamins
Lentivirus Infections
Micronutrients

ClinicalTrials.gov processed this record on January 15, 2009